<DOC>
	<DOC>NCT02607956</DOC>
	<brief_summary>This study will evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults at Week 48.</brief_summary>
	<brief_title>Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Key Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV1 infection) except the use for PrEP (preexposure prophylaxis) or PEP (postexposure prophylaxis), up to one month prior to screening Plasma HIV 1 RNA levels ≥ 500 copies/mL at screening Adequate renal function: Estimated glomerular filtration rate ≥ 30 mL/min (≥ 0.50 mL/sec) according to the Cockcroft Gault formula Key An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening Decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding) Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance Females who are pregnant (as confirmed by positive serum pregnancy test) Females who are breastfeeding Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>